VEA
ZNTL icon

Virtus ETF Advisers’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Virtus ETF Advisers’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,713
Closed -$68.8K – 811
2024
Q4 		$68.8K Buy
22,713
+13,030
+135% +$42.7K 0.03% 387
2024
Q3 		$35.6K Buy
9,683
+174
+2% +$632 0.02% 447
2024
Q2 		$38.9K Buy
9,509
+3,719
+64% +$41.5K 0.02% 446
2024
Q1 		$91.3K Sell
5,790
-399
-6% -$5.49K 0.05% 378
2023
Q4 		$93.8K Buy
6,189
+2,177
+54% +$31.8K 0.06% 390
2023
Q3 		$80.5K Sell
4,012
-403
-9% -$10.2K 0.05% 359
2023
Q2 		$125K Sell
4,415
-650
-13% -$15.6K 0.07% 326
2023
Q1 		$87.1K Sell
5,065
-1,945
-28% -$39.4K 0.05% 368
2022
Q4 		$141K Buy
7,010
+2,191
+45% +$47.1K 0.07% 362
2022
Q3 		$104K Buy
4,819
+33
+0.7% +$902 0.04% 419
2022
Q2 		$134K Buy
4,786
+2,617
+121% +$69.3K 0.05% 341
2022
Q1 		$100K Sell
2,169
-136
-6% -$7.34K 0.04% 303
2021
Q4 		$194K Sell
2,305
-1,489
-39% -$115K 0.07% 220
2021
Q3 		$253K Sell
3,794
-198
-5% -$11.4K 0.11% 217
2021
Q2 		$212K Sell
3,992
-1,827
-31% -$97.8K 0.09% 305
2021
Q1 		$252K Buy
5,819
+108
+2% +$4.65K 0.11% 287
2020
Q4 		$297K Buy
+5,711
New +$258K 0.12% 216

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtus ETF Advisers's ZNTL Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 22,713 shares — an estimated $68.8K sold.

Virtus ETF Advisers first reported a position in ZNTL in Q4 2020 and held it in 17 quarters. The position peaked at $297K in Q4 2020. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 22,713 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $68.8K.
  • Virtus ETF Advisers first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 17 quarters.
  • Virtus ETF Advisers's Zentalis Pharmaceuticals position peaked at $297K in Q4 2020.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.